Literature DB >> 17167981

Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.

Q Li1, B Xu, L Fu, X S Hao.   

Abstract

The aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC). The expression of VEGF, Ang2, ephrinB2 and EG-VEGF was detected by RT-PCR in 54 cases HCC without PVTT (group A), 9 cases HCC with PVTT (group B), 10 normal liver tissues (group D) and 10 cirrhosis tissues (group C). The samples were also stained with CD34 by immunohistochemistry. Quantitation of microvessel density (MVD) and semi-quantitation of VEGF, Ang2, ephrinB2 and EG-VEGF expression were analyzed to find the relations. The MVD was 146.69 +/- 77.79, 214.07 +/- 54.41, 32.85 +/- 8.49 and 34.83 +/- 8.29 in group A-D respectively with significant difference (F = 19.77, P = 0.000). The MVD in group A was higher than that in group C P = 0.006, but lower than that in group B P < or = 0.05 or 0.01. The expression levels of VEGF165, VEGF189, Ang2 and EG-VEGF mRNA were significantly different among the groups. The expression levels of VEGF165, Ang2 and EG-VEGF mRNA in group A were all higher than those in group C, but lower than those in group B P < 0.05 or 0.01. The MVD was significantly correlated with VEGF165, VEGF189, Ang2 and EG-VEGF mRNA with Spearman's related coefficient being 0.764, 0.510, 0.640 and 0.366 in HCC (P = 0.000, 0.000 0.000 and 0.003). In conclusion VEGF, Ang2 and EG-VEGF mRNA may play a role in angiogenesis and carcinogenesis of HCC. They can promote PVTT formation in HCC by modulating angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167981

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  22 in total

Review 1.  Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.

Authors:  L V Klotz; M E Eichhorn; B Schwarz; H Seeliger; M K Angele; K-W Jauch; Christiane J Bruns
Journal:  Langenbecks Arch Surg       Date:  2012-03-14       Impact factor: 3.445

2.  Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy.

Authors:  Mi Yean Yang; Soung Won Jeong; Dong Kyun Kim; Sang Gyune Kim; Jae Young Jang; Young Seok Kim; Joon Seong Lee; Boo Sung Kim; Jung Hoon Kim; Yong Jae Kim
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

3.  Foxp3+ regulatory T cells and the formation of portal vein tumour thrombus in patients with hepatocellular carcinoma.

Authors:  Shun Li Shen; Li Jian Liang; Bao Gang Peng; Qiang He; Ming Kuang; Jia Ming Lai
Journal:  Can J Surg       Date:  2011-04       Impact factor: 2.089

4.  Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.

Authors:  Linda Calistri; Cesare Cordopatri; Cosimo Nardi; Elena Gianni; Fabio Marra; Stefano Colagrande
Journal:  Mol Clin Oncol       Date:  2017-01-16

5.  Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.

Authors:  Min Su Kim; Young-Joo Jin; Jin-Woo Lee; Jung-Il Lee; Young Soo Kim; Sun Young Lee; Myoung Hun Chae
Journal:  World J Gastrointest Oncol       Date:  2013-02-15

6.  Intravital assessment of angioarchitecture in rat hepatocellular nodules using in vivo fluorescent microscopy.

Authors:  Yi Liu; Tao Lu; Congcong Wang; Hui Li; Ke Xu; Peiling Li
Journal:  Quant Imaging Med Surg       Date:  2019-06

Review 7.  Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.

Authors:  Ying-Chun Shen; Chiun Hsu; Ann-Lii Cheng
Journal:  J Gastroenterol       Date:  2010-06-22       Impact factor: 6.772

8.  Complete response for advanced liver cancer during sorafenib therapy: case report.

Authors:  Rodolfo Sacco; Irene Bargellini; Giannelli Gianluigi; Marco Bertini; Elena Bozzi; Emanuele Altomare; Valentina Battaglia; Antonio Romano; Michele Bertoni; Alfonso Capria; Giampaolo Bresci; Carlo Bartolozzi
Journal:  BMC Gastroenterol       Date:  2011-01-17       Impact factor: 3.067

9.  The molecular pathogenesis and clinical implications of hepatocellular carcinoma.

Authors:  Makoto Meguro; Toru Mizuguchi; Masaki Kawamoto; Koichi Hirata
Journal:  Int J Hepatol       Date:  2011-12-04

Review 10.  Molecular diversity of VEGF-A as a regulator of its biological activity.

Authors:  Jeanette Woolard; Heather S Bevan; Steven J Harper; David O Bates
Journal:  Microcirculation       Date:  2009-06-01       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.